“Global Ophthalmic Drugs market valued at $23bn in 2017” says Visiongain report

19 July 2017
Pharma

Visiongain’ has launched a new pharma report Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2018 – 2028: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.

A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas. Key patent expirations have affected revenues in this market in recent years, particularly in the glaucoma segment.

The lead analyst of the report commented “Considerable success in the ophthalmic pharmaceutical market is likely for therapies that will accommodate the large unmet need for pharmacological therapies for currently-untreated ophthalmic conditions. Certain conditions, where surgery is the only treatment, have an unmet patient need for pharmaceutical treatments.

However, to be commercially successful, new products must overcome significant hurdles. These include the challenge of demonstrating efficacy and safety during regulatory approval (especially for chronic diseases), achieving adequate reimbursement, and addressing the growing threat of generic competition.”

Leading companies featured in the report include Akorn, Alcon, Allergan, Bausch & Lomb, Bayer, Novartis, Pfizer, Regeneron, Roche, Santen, Senju, Valeant

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever